Drug intelligence / Profile preview

oNKo-044

Development stage: Preclinical
Lead developer: oNKo-innate
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Oral, Intravenous

Overview

oNKo-044 is a preclinical-stage immuno-oncology drug developed by oNKo-innate Pty Ltd. It functions as an Interleukin-12 (IL-12) modulator, aiming to enhance anti-tumor immune responses. IL-12 is a cytokine known for its role in stimulating T cells and natural killer (NK) cells, which are crucial components of the immune system's fight against cancer. The drug is being investigated for its potential in treating neoplasms.

Targets

IL12 (Interleukin-12)

Beyond the preview

Go deeper on oNKo-044.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on oNKo-044.

Explore the full profile